SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

18 Jul 2025 08:30:40 By Nasdaq GlobeNewswire

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

18 Jul 2025 08:30:23 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

20 Jun 2025 05:00:52 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

23 May 2025 05:00:00 By Nasdaq GlobeNewswire

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

27 Apr 2025 23:13:33 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

27 Apr 2025 07:35:13 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

20 Feb 2025 03:30:32 By Nasdaq GlobeNewswire

UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 

11 Feb 2025 17:20:22 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 

11 Feb 2025 14:27:40 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

30 Jan 2025 04:00:50 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference

13 Jan 2025 03:30:33 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

03 Jan 2025 03:30:46 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

26 Nov 2024 04:00:26 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference

12 Nov 2024 06:25:59 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

12 Nov 2024 03:30:21 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

11 Nov 2024 04:00:56 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology

11 Nov 2024 03:30:11 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting

07 Nov 2024 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

05 Nov 2024 04:00:32 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

22 Oct 2024 04:00:14 By Nasdaq GlobeNewswire